Cardiovalve TTVR System; a Novel Technology for Patients with Tricuspid Regurgitation
We Recommend
Disclosures
Within the last 24 months, I have financial relationship(s) or affiliation(s) with a manufacturer, marketer, reseller, or distributor of a healthcare product or service involved in the management of patients with any cardiovascular disease to include devices, drugs, and digital health care products listed below:
- Shareholder (Personal) - 4Tech Cardio; Cardiovalve; Cardiogard; Magenta; SwissVortex; Perfect
- Consultant Fee/Honoraria/Speaker's Bureau (Both) - Abbott Vascular; Cardiovalve; Edwards Lifesciences
- Grant Support/Research Contract (Institutional) - Abbott Vascular; Biotronik; Boston Scientific Corporation; Edwards Lifesciences; Medtronic; NVT; Terumo Medical Corporation
- Royalty/Intellectual Property Rights (Personal) - Edwards Lifesciences
- Consultant Fee/Honoraria/Speaker's Bureau (Personal) - Magenta; Swissvortex Perifect; Xeltis; Perifect; TransseptalSolutions
- Consultant Fee/Honoraria/Speaker's Bureau (Institutional) - Medtronic
- Ownership Interest/Partnership/Principal (Personal) - Transseptal Solutions